Table 3.
List of burn-responsive proteins previously known to be associated with either inflammatory or burn responses.
| Gene symbol | Protein name | Functions | Burn-T1/Control (Log2Ratio) | Burn-T2/Control (Log2Ratio) | UP or DOWN regulation |
|---|---|---|---|---|---|
| TREML1 | Trem-like transcript 1 protein | Activated by platelet activation | 1.6 | 1.9 | UP |
| S100A9 | Protein S100-A9 | Immune response | 1.3 | 1.0 | UP |
| VCAM1 | Vascular cell adhesion molecule 1 | Inflammation marker | 0.8 | 0.3 | UP |
| SERPINA3 | Alpha-1-antichymotrypsin | Positive acute phase protein | 0.4 | 0.6 | UP |
| SERPINA2 | Alpha-1-antitrypsin-related protein | Positive acute phase protein | 0.8 | 1.2 | UP |
| MBL2 | Mannose-binding protein C | Positive acute phase protein | 0.6 | −0.1 | UP |
| VWF | von Willebrand factor | Positive acute phase protein | 0.5 | 0.2 | UP |
| CD44 | CD44 antigen | Immune response | 0.5 | 1.5 | UP |
| B2M | Beta-2-microglobulin | Immune response | 0.5 | 1.1 | UP |
| FGG | Fibrinogen gamma chain | Positive acute phase protein, | 0.5 | 1.0 | UP |
| FGB | Fibrinogen beta chain | Positive acute phase protein | 0.3 | 0.6 | UP |
| CRP | C-reactive protein | Positive acute phase protein | 0.4 | 1.0 | UP* |
| MASP2 | Mannan-binding lectin serine protease 2 | Positive acute phase protein | 0.3 | 1.3 | UP |
| HSPA5 | HSPA5 protein | Immune response | 0.3 | 0.8 | UP |
| ENO1 | Alpha-enolase | Inflammatory mediator55 | 0.3 | 0.9 | UP |
| ALCAM | CD166 antigen | Inflammatory disorder | 0.3 | −0.5 | UP |
| MASP1 | mannan-binding lectin serine protease 1 | Positive acute phase protein | 0.3 | −0.5 | UP |
| C9 | Complement component C9 | Positive acute phase protein | 0.0 | 0.7 | UP |
| SERPING1 | Plasma protease C1 inhibitor | Positive acute phase protein | 0.2 | 0.7 | UP |
| ITIH3 | Inter-alpha-trypsin inhibitor heavy chain H3 | Positive acute phase protein | 0.5 | 0.4 | UP |
| RBP4 | Plasma retinol-binding protein | Negative acute phase protein | 0.0 | −0.3 | DOWN* |
| SERPINC1 | Antithrombin III | Inflammatory marker | −0.3 | −0.5 | DOWN |
| ITIH1 | Inter-alpha-trypsin inhibitor heavy chain H1 precursor | Negative acute phase protein | −0.4 | −0.5 | DOWN |
| ITIH2 | Inter-alpha-trypsin inhibitor heavy chain H2 | Negative acute phase protein | −0.6 | −0.8 | DOWN |
| SPARC | SPARC | Inflammatory marker | −0.5 | 0.8 | DOWN |
| TTR | Transthyretin | Negative acute phase protein | −0.5 | −0.6 | DOWN* |
| APOH | Beta-2-glycoprotein 1 | Negative acute phase protein | −0.6 | −0.5 | DOWN |
| C4A;C4B** | Complement C4-A | Positive acute phase protein | −0.6 | −0.3 | DOWN |
| FN1 | Isoform 1 of Fibronectin precursor | Negative acute phase protein | −0.7 | −0.6 | DOWN |
| AHSG | Alpha-2-HS-glycoprotein | Negative acute phase protein | −0.8 | −1.0 | DOWN |
| PLG | Plasminogen | Acute phase protein | −0.8 | −0.6 | DOWN |
| PON1 | Serum paraoxonase/arylesterase 1 | Inflammatory marker | −0.9 | −1.1 | DOWN |
| HRG | Histidine-rich glycoprotein | Negative acute phase protein | −2.0 | −1.7 | DOWN |
| KLKB1 | Plasma prekallikrein | Acute phase response | −1.3 | −1.1 | DOWN |
| KNG1 | Isoform HMW of Kininogen-1 | Acute phase response | −0.5 | −0.5 | DOWN |
*
Post-burn response of these proteins was reported by Jeschke et al.38
**
The observed abundance changes oppose previously reported literature knowledge.